Lenalidomid Axiromed (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑E3 ubiquitin ligase complex, altering its substrate specificity. This triggers degradation of transcription factors Ikaros and Aiolos, leading to reduced proliferation of malignant plasma cells, enhanced immune cell activity, and inhibition of new blood‑vessel formation in the bone‑marrow environment.

The specific dose and dosing schedule of Lenalidomid Axiromed are determined by the prescribing physician based on the patient’s condition, disease stage, renal function, and other clinical factors. The prescriber will set the appropriate regimen and adjust it as needed during therapy.

Lenalidomid Axiromed is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because it can cause severe fetal harm. It should not be used by nursing mothers, as it may be excreted in breast milk and pose a risk to the infant.

To request Lenalidomid Axiromed, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lenalidomide is a second‑generation immunomodulatory agent, offering greater potency and a more favorable safety profile than thalidomide, while being less myelosuppressive than pomalidomide. It is often preferred when a balance between efficacy and tolerability is needed, especially in patients with del(5q) myelodysplastic syndromes.

Store Lenalidomid Axiromed at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze the product.

Lenalidomid Axiromed is taken orally, usually with a glass of water. It may be taken with or without food, but the prescriber may give specific instructions to minimize gastrointestinal upset. Swallow the tablet whole; do not crush or split unless directed.

The most serious risks include severe neutropenia leading to infection, venous thromboembolism such as deep‑vein thrombosis or pulmonary embolism, and the potential development of secondary primary malignancies. Patients should be monitored closely for signs of infection, clotting events, and new cancers.

Lenalidomid Axiromed should not be used by pregnant women or women who may become pregnant, because of its teratogenicity. It is also contraindicated in patients with known hypersensitivity to lenalidomide or its excipients, and caution is required in those with severe renal impairment without appropriate dose adjustment.